D. Boral Capital Reiterates “Buy” Rating for Quince Therapeutics (NASDAQ:QNCX)

Quince Therapeutics (NASDAQ:QNCX)‘s stock had its “buy” rating restated by equities research analysts at D. Boral Capital in a research note issued to investors on Thursday,Benzinga reports. They currently have a $4.00 target price on the stock. D. Boral Capital’s price target points to a potential upside of 133.24% from the stock’s current price.

QNCX has been the topic of several other research reports. Citigroup started coverage on Quince Therapeutics in a research note on Tuesday, August 5th. They issued an “outperform” rating on the stock. Citizens Jmp started coverage on Quince Therapeutics in a research report on Tuesday, August 5th. They issued a “strong-buy” rating and a $9.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Quince Therapeutics in a report on Wednesday, October 8th. JMP Securities reduced their price target on shares of Quince Therapeutics from $9.00 to $8.00 and set a “market outperform” rating on the stock in a research note on Tuesday, August 12th. Finally, Zacks Research upgraded shares of Quince Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 26th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

Quince Therapeutics Price Performance

Shares of NASDAQ:QNCX traded up $0.01 during trading on Thursday, reaching $1.72. 116,964 shares of the company traded hands, compared to its average volume of 257,599. The firm has a market capitalization of $92.11 million, a PE ratio of -1.57 and a beta of 1.07. The company’s 50 day moving average is $1.71 and its two-hundred day moving average is $1.52. Quince Therapeutics has a 52 week low of $0.72 and a 52 week high of $2.45. The company has a quick ratio of 5.00, a current ratio of 5.00 and a debt-to-equity ratio of 1.45.

Quince Therapeutics (NASDAQ:QNCX) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.05). As a group, sell-side analysts predict that Quince Therapeutics will post -1.21 earnings per share for the current year.

Hedge Funds Weigh In On Quince Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd bought a new position in Quince Therapeutics in the 2nd quarter valued at about $37,000. Virtu Financial LLC lifted its holdings in shares of Quince Therapeutics by 48.4% in the first quarter. Virtu Financial LLC now owns 43,332 shares of the company’s stock valued at $58,000 after purchasing an additional 14,128 shares in the last quarter. GSA Capital Partners LLP boosted its position in shares of Quince Therapeutics by 158.0% during the third quarter. GSA Capital Partners LLP now owns 87,235 shares of the company’s stock valued at $142,000 after buying an additional 53,417 shares during the last quarter. Bridgeway Capital Management LLC grew its holdings in Quince Therapeutics by 20.9% during the second quarter. Bridgeway Capital Management LLC now owns 128,617 shares of the company’s stock worth $212,000 after buying an additional 22,200 shares in the last quarter. Finally, Rockefeller Capital Management L.P. purchased a new stake in Quince Therapeutics in the 2nd quarter valued at $280,000. 30.75% of the stock is currently owned by institutional investors.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.